New shot aims to tame a stubborn heart risk factor
NCT ID NCT07172646
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 24 times
Summary
This study tests an experimental drug called SRSD216, given as an injection under the skin, in people with high levels of lipoprotein(a) – a genetic risk factor for heart disease. The trial has two parts: first to check safety and find the right dose, then to confirm the dose in a larger group. About 84 adults with elevated Lp(a) will participate, and the main goal is to see if the drug is safe and well-tolerated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERLIPOPROTEINEMIA (A) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site 01
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.